Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > durvalumab
durvalumab
Thursday 9 June 2016
Imfinzi
| WP |
Durvalumab is one of PD-L1 inhibitors . It ismonoclonal antibody being investigated for the treatment of cancer. It targets programmed death ligand-1 (PD-L1), developed by MedImmune.
Clinical trials
non-small cell lung cancer (NSCLC)
- - trial combining durvalumab and gefitinib in NSCLC
advanced metastatic urothelial bladder
See also
PD-L1 inhibitors
immune checkpoint